
Photo: Depositphotos
Jun 2, 2025, 09:18
Excellence in Oncology Care Shares 5-Year KN564 Data on Adjuvant Pembrolizumab in RCC
Excellence in Oncology Care – EIOC posted on X:
“5 year follow up for adjuvant pembro in RCC (KN564). DFS (5yr 52% v61% – HR0.71). OS (5yr 82% vs 88% HR0.66). Maintained KM curve separation.”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 02:12
Jun 4, 2025, 01:58
Jun 4, 2025, 00:35